Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SUNIL S DHAWAN

Allopathic & Osteopathic Physicians Dermatology

NPI
1326018987
CMS profile
331770
Location
FREMONT, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$3,237.07

159 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,923.65 154
Education $283.42 4
Grant $30.00 1

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 159 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SUNIL S DHAWAN

NPI 1326018987 · CMS profile ID 331770

Allopathic & Osteopathic Physicians / Dermatology

FREMONT, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 159 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1326018987?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SUNIL S DHAWAN, NPI 1326018987, CMS profile ID 331770. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 159 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1326018987?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). SUNIL S DHAWAN, NPI 1326018987, CMS profile ID 331770. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 159 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1326018987?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
SUNIL S DHAWAN, NPI 1326018987, CMS profile ID 331770, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 159 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1326018987?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

159 matching records · $3,237.07 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 159 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 159.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Dermavant Sciences, Inc. $6.2309/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127861754 CMS
Galderma Laboratories, L.P. $16.9809/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145294491 CMS
ABBVIE INC. $25.6909/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103635546 CMS
Janssen Biotech, Inc. $14.1109/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078296349 CMS
Arcutis Biotherapeutics, Inc. $21.2609/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121075161 CMS
ABBVIE INC. $13.6609/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103635544 CMS
ABBVIE INC. $20.3009/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103635542 CMS
Amgen Inc. $25.5508/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117540944 CMS
Galderma Laboratories, L.P. $21.6508/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145294489 CMS
PFIZER INC. $16.4008/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131880447 CMS
LEO Pharma Inc. $12.4308/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152626197 CMS
Regeneron Healthcare Solutions, Inc. $25.4308/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114037119 CMS
Dermavant Sciences, Inc. $14.0608/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127861752 CMS
Arcutis Biotherapeutics, Inc. $19.2008/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121075159 CMS
Dermavant Sciences, Inc. $99.0608/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127861750 CMS
LEO Pharma Inc. $14.9808/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152626195 CMS
ABBVIE INC. $25.3708/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103635540 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $22.4508/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153817639 CMS
ABBVIE INC. $11.0008/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103635538 CMS
ABBVIE INC. $30.0607/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103635536 CMS
Dermavant Sciences, Inc. $12.3807/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127861748 CMS
GENZYME CORPORATION $17.2907/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139625756 CMS
Janssen Scientific Affairs, LLC $21.0807/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078844757 CMS
Dermavant Sciences, Inc. $1.9107/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127861746 CMS
LEO Pharma Inc. $10.4307/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152626193 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $94.9907/19/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152205763 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $27.1907/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152205773 CMS
PFIZER INC. $20.9307/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131788553 CMS
Dermavant Sciences, Inc. $22.3307/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127861744 CMS
LEO Pharma Inc. $13.8907/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152626191 CMS
Janssen Biotech, Inc. $11.8207/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078296351 CMS
Amgen Inc. $24.7807/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117540942 CMS
LEO Pharma Inc. $7.6707/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152626189 CMS
Janssen Biotech, Inc. $99.9907/03/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078296649 CMS
Incyte Corporation $13.1307/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141319479 CMS
ABBVIE INC. $29.9706/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103635534 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $23.5506/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153817637 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $1.5206/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152205767 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $26.3606/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152205769 CMS
ABBVIE INC. $33.7506/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103635532 CMS
PFIZER INC. $18.8506/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131609904 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $22.3506/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153817631 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $21.5106/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153817633 CMS
Galderma Laboratories, L.P. $21.5906/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145294487 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $6.3006/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152205765 CMS
LEO Pharma Inc. $7.0506/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152626187 CMS
Dermavant Sciences, Inc. $16.1305/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127861742 CMS
PFIZER INC. $4.5805/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1130914542 CMS
ABBVIE INC. $12.0805/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103635530 CMS
Arcutis Biotherapeutics, Inc. $40.2405/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121075157 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $19,781.63 106
PY2020 $6,095.80 60
PY2021 $5,667.26 82
PY2022 $7,247.43 94
PY2023 $2,846.93 117
PY2024 $3,237.07 159
PY2025 $2,826.80 102

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $919,287.41 167
PY2024 Principal investigator $756,940.35 201
PY2023 Recipient $789.81 1
PY2023 Principal investigator $547,649.68 157
PY2022 Principal investigator $319,459.27 65
PY2021 Recipient $89.85 1
PY2021 Principal investigator $749,576.98 140
PY2020 Recipient $2,374.15 3
PY2020 Principal investigator $935,586.92 119
PY2019 Recipient $35,982.45 7
PY2019 Principal investigator $758,098.81 115

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

167 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $12,000.00 12/26/2025 Non-covered Recipient Entity
Center For Dermatology Clinical Research
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) No dispute reported 06/30/2026 1235998222
Principal investigator 1 Janssen Research & Development, LLC $1,380.00 12/25/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RES
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175344989
Principal investigator 1 SANOFI US SERVICES INC. $2,717.00 12/22/2025 Non-covered Recipient Entity
Center For Dermatology Clinical Research Inc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226090784
Principal investigator 1 SANOFI US SERVICES INC. $1,956.10 12/22/2025 Non-covered Recipient Entity
Center For Dermatology Clinical Research Inc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226116645
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,900.00 12/18/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431008
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,480.00 12/15/2025 Non-covered Recipient Entity
Center for Dermatology Clinical Research, Inc.
Study Comparing Tapinarof Cream 1% To VTAMA (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis No dispute reported 06/30/2026 1244051685
Principal investigator 1 SANOFI US SERVICES INC. $607.50 12/08/2025 Non-covered Recipient Entity
Center For Dermatology Clinical Research Inc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226116635
Principal investigator 1 SANOFI US SERVICES INC. $3,054.00 12/08/2025 Non-covered Recipient Entity
Center For Dermatology Clinical Research Inc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226116641
Principal investigator 1 Incyte Corporation $8,435.90 12/04/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240514874
Principal investigator 1 Incyte Corporation $10,027.20 12/04/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240514878
Principal investigator 1 Vanda Pharmaceuticals Inc. $7,100.00 12/03/2025 Non-covered Recipient Entity
CTR FOR DERMATOLOGY CLINICAL RESEARCH
AN OPEN LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY AND EFFICACY OF TRICHOSTATIN A IN PATIENTS WITH MILD TO SEVERE ONYCHOMYCOSIS No dispute reported 06/30/2026 1232947079
Principal investigator 1 Janssen Research & Development, LLC $1,380.00 12/01/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RES
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175344981
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,909.20 12/01/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICA
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289053
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,781.60 11/26/2025 Non-covered Recipient Entity
Center for Dermatology Clinical Research, Inc.
A Phase 1b, Open-Label Trial to Assess Safety and Exploratory Efficacy of TEV-53408 in Participants With Vitiligo No dispute reported 06/30/2026 1244051701
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $13,129.60 11/26/2025 Non-covered Recipient Entity
Center for Dermatology Clinical Research, Inc.
A Phase 1b, Open-Label Trial to Assess Safety and Exploratory Efficacy of TEV-53408 in Participants With Vitiligo No dispute reported 06/30/2026 1244051703
Principal investigator 1 Incyte Corporation $5,840.00 11/25/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240514851
Principal investigator 1 Incyte Corporation $2,211.30 11/25/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240514860
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $11,315.00 11/24/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata No dispute reported 06/30/2026 1252797002
Principal investigator 1 SANOFI US SERVICES INC. $1,950.00 11/18/2025 Non-covered Recipient Entity
Center For Dermatology Clinical Research Inc
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226108615
Principal investigator 1 SANOFI US SERVICES INC. $6,716.20 11/17/2025 Non-covered Recipient Entity
Center For Dermatology Clinical Research Inc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226090779
Principal investigator 1 Incyte Corporation $1,368.00 11/14/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240514864
Principal investigator 1 SANOFI US SERVICES INC. $65.00 11/13/2025 Non-covered Recipient Entity
Center For Dermatology Clinical Research Inc
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226108610
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,118.75 11/13/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431006
Principal investigator 1 SANOFI US SERVICES INC. $2,812.50 11/10/2025 Non-covered Recipient Entity
Center For Dermatology Clinical Research Inc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226116628
Principal investigator 1 Incyte Corporation $1,003.50 11/07/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240514855
Principal investigator 1 Incyte Corporation $4,930.60 11/06/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC
An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo No dispute reported 06/30/2026 1240514868
Principal investigator 1 Novartis Pharmaceuticals Corporation $77.00 11/03/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH INCORPORATION
A Multicenter, Randomized, Participant- and Investigator -Blinded, Placebo-controlled, Phase 2a Study to Assess the Efficacy, Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1190305181
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $8,197.50 10/30/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431002
Principal investigator 1 Incyte Corporation $1,937.70 10/29/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240514847
Principal investigator 1 Vanda Pharmaceuticals Inc. $13,385.00 10/28/2025 Non-covered Recipient Entity
CTR FOR DERMATOLOGY CLINICAL RESEARCH
AN OPEN LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY AND EFFICACY OF TRICHOSTATIN A IN PATIENTS WITH MILD TO SEVERE ONYCHOMYCOSIS No dispute reported 06/30/2026 1232946765
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,200.00 10/27/2025 Non-covered Recipient Entity
Center for Dermatology Clinical Research, Inc.
A Phase 1b, Open-Label Trial to Assess Safety and Exploratory Efficacy of TEV-53408 in Participants With Vitiligo No dispute reported 06/30/2026 1244051699
Principal investigator 1 Novartis Pharmaceuticals Corporation $12,000.00 10/23/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC
A Multicenter, Randomized, Participant- and Investigator -Blinded, Placebo-controlled, Phase 2a Study to Assess the Efficacy, Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1190309472
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $7,068.75 10/23/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431004
Principal investigator 1 Janssen Research & Development, LLC $2,500.00 10/22/2025 Non-covered Recipient Entity
Ctr For Derm Clinic Rsrch
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175170180
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,969.50 10/22/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICA
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223287283
Principal investigator 1 SANOFI US SERVICES INC. $11,089.00 10/20/2025 Non-covered Recipient Entity
Center For Dermatology Clinical Research Inc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226116623
Principal investigator 1 SANOFI US SERVICES INC. $895.00 10/16/2025 Non-covered Recipient Entity
Center For Dermatology Clinical Research Inc
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226108621
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,174.14 10/14/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH INCORPORATION
A Multicenter, Randomized, Participant- and Investigator -Blinded, Placebo-controlled, Phase 2a Study to Assess the Efficacy, Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1190305179
Principal investigator 1 SANOFI US SERVICES INC. $2,500.00 10/14/2025 Non-covered Recipient Entity
Center For Dermatology Clinical Research Inc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226116618
Principal investigator 1 Incyte Corporation $1,699.20 10/09/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240514843
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $8,165.64 10/09/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431000
Principal investigator 1 Novartis Pharmaceuticals Corporation $243.78 10/08/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH INCORPORATION
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190305183
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,847.94 10/08/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH INCORPORATION
A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup No dispute reported 06/30/2026 1190305187
Principal investigator 1 SANOFI US SERVICES INC. $15,300.00 10/06/2025 Non-covered Recipient Entity
Center For Dermatology Clinical Research Inc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226116607
Principal investigator 1 SANOFI US SERVICES INC. $3,321.90 10/06/2025 Non-covered Recipient Entity
Center For Dermatology Clinical Research Inc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226116612
Principal investigator 1 Incyte Corporation $3,010.50 10/03/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240514839
Principal investigator 1 Vanda Pharmaceuticals Inc. $13,845.00 10/03/2025 Non-covered Recipient Entity
CTR FOR DERMATOLOGY CLINICAL RESEARCH
AN OPEN LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY AND EFFICACY OF TRICHOSTATIN A IN PATIENTS WITH MILD TO SEVERE ONYCHOMYCOSIS No dispute reported 06/30/2026 1232946444
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $14,446.90 10/01/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICA
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223286069
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $10,400.00 09/30/2025 Non-covered Recipient Entity
Center for Dermatology Clinical Research, Inc.
Study Comparing Tapinarof Cream 1% To VTAMA (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis No dispute reported 06/30/2026 1244051683
Principal investigator 1 Janssen Research & Development, LLC $172.00 09/29/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RES EARCH INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175344972
Principal investigator 1 Incyte Corporation $2,790.90 09/23/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240514836
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $11,926.40 09/17/2025 Non-covered Recipient Entity
Center for Dermatology Clinical Research, Inc.
A Phase 1b, Open-Label Trial to Assess Safety and Exploratory Efficacy of TEV-53408 in Participants With Vitiligo No dispute reported 06/30/2026 1244051697
Principal investigator 1 Incyte Corporation $1,094.40 09/12/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240514827
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $160.00 09/08/2025 Non-covered Recipient Entity
Center for Dermatology Clinical Research, Inc.
Study Comparing Tapinarof Cream 1% To VTAMA (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis No dispute reported 06/30/2026 1244051681
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,507.20 09/08/2025 Non-covered Recipient Entity
Center for Dermatology Clinical Research, Inc.
A Phase 1b, Open-Label Trial to Assess Safety and Exploratory Efficacy of TEV-53408 in Participants With Vitiligo No dispute reported 06/30/2026 1244051695
Principal investigator 1 Incyte Corporation $3,806.10 09/04/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240514831
Principal investigator 1 Janssen Research & Development, LLC $3,506.00 09/04/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RES EARCH INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175344965
Principal investigator 1 Vanda Pharmaceuticals Inc. $14,345.00 09/04/2025 Non-covered Recipient Entity
CTR FOR DERMATOLOGY CLINICAL RESEARCH
AN OPEN LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY AND EFFICACY OF TRICHOSTATIN A IN PATIENTS WITH MILD TO SEVERE ONYCHOMYCOSIS No dispute reported 06/30/2026 1232946236
Principal investigator 1 Incyte Corporation $1,699.20 08/26/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240514816
Principal investigator 1 Incyte Corporation $1,091.70 08/21/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240514820
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,200.00 08/20/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223284445
Principal investigator 1 SANOFI US SERVICES INC. $325.00 08/19/2025 Non-covered Recipient Entity
Center For Dermatology Clinical Research Inc
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226098099
Principal investigator 1 Janssen Research & Development, LLC $1,602.00 08/11/2025 Non-covered Recipient Entity
Ctr For Derm Clinic Rsrch
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175170316
Principal investigator 1 SANOFI US SERVICES INC. $2,034.90 08/11/2025 Non-covered Recipient Entity
Center For Dermatology Clinical Research Inc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226116597
Principal investigator 1 Incyte Corporation $6,789.60 08/07/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240514823
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $21,476.77 08/07/2025 Non-covered Recipient Entity
Center for Dermatology Clinical Research, Inc.
A Phase 1b, Open-Label Trial to Assess Safety and Exploratory Efficacy of TEV-53408 in Participants With Vitiligo No dispute reported 06/30/2026 1244051693
Principal investigator 1 Vanda Pharmaceuticals Inc. $9,525.00 08/06/2025 Non-covered Recipient Entity
CTR FOR DERMATOLOGY CLINICAL RESEARCH
AN OPEN LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY AND EFFICACY OF TRICHOSTATIN A IN PATIENTS WITH MILD TO SEVERE ONYCHOMYCOSIS No dispute reported 06/30/2026 1232946055
Principal investigator 1 Vanda Pharmaceuticals Inc. $7,000.00 08/06/2025 Non-covered Recipient Entity
CTR FOR DERMATOLOGY CLINICAL RESEARCH
AN OPEN LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY AND EFFICACY OF TRICHOSTATIN A IN PATIENTS WITH MILD TO SEVERE ONYCHOMYCOSIS No dispute reported 06/30/2026 1232946059
Principal investigator 1 Vanda Pharmaceuticals Inc. $5,975.00 08/06/2025 Non-covered Recipient Entity
CTR FOR DERMATOLOGY CLINICAL RESEARCH
AN OPEN LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY AND EFFICACY OF TRICHOSTATIN A IN PATIENTS WITH MILD TO SEVERE ONYCHOMYCOSIS No dispute reported 06/30/2026 1232946063
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $9,000.00 08/04/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246430998
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,999.10 08/01/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283715
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $13,919.10 08/01/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283717
Principal investigator 1 SANOFI US SERVICES INC. $3,566.00 07/14/2025 Non-covered Recipient Entity
Center For Dermatology Clinical Research Inc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226116577
Principal investigator 1 Incyte Corporation $7,104.60 07/10/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240514811
Principal investigator 1 SANOFI US SERVICES INC. $2,608.75 07/10/2025 Non-covered Recipient Entity
Center For Dermatology Clinical Research Inc
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226098110
Principal investigator 1 SANOFI US SERVICES INC. $4,698.00 07/07/2025 Non-covered Recipient Entity
Center For Dermatology Clinical Research Inc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226116583
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,830.60 07/01/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223281982
Principal investigator 1 Janssen Research & Development, LLC $2,760.00 06/26/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RES EARCH INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175344996
Principal investigator 1 Incyte Corporation $820.80 06/24/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240514798
Principal investigator 1 Incyte Corporation $2,802.60 06/19/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240514803
Principal investigator 1 SANOFI US SERVICES INC. $3,236.00 06/16/2025 Non-covered Recipient Entity
Center For Dermatology Clinical Research Inc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226116558
Principal investigator 1 Incyte Corporation $3,567.60 06/12/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240514807
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $88.00 06/11/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184205829
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $88.00 06/11/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184205831
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $88.00 06/11/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184205833
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $88.00 06/11/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184205835
Principal investigator 1 SANOFI US SERVICES INC. $1,534.50 06/09/2025 Non-covered Recipient Entity
Center For Dermatology Clinical Research Inc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226116554
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $13,890.50 06/04/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223280748
Principal investigator 1 Novartis Pharmaceuticals Corporation $12,528.00 06/01/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH INCORPORATION
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190305185
Principal investigator 1 Incyte Corporation $1,003.50 05/28/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240514795
Principal investigator 1 SANOFI US SERVICES INC. $5,100.00 05/27/2025 Non-covered Recipient Entity
Center For Dermatology Clinical Research Inc
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Proof-of-concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226116540
Principal investigator 1 Incyte Corporation $78.30 05/22/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240514791
Principal investigator 1 Eli Lilly and Company $11,102.00 05/21/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC
OBSERVATION PRIORITY E SHORT - LEBRIKIZUMAB - ATOPIC DERMATITIS No dispute reported 06/30/2026 1187875575
Principal investigator 1 SANOFI US SERVICES INC. $4,582.00 05/19/2025 Non-covered Recipient Entity
Center For Dermatology Clinical Research Inc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226116566
Principal investigator 1 SANOFI US SERVICES INC. $7,400.00 05/19/2025 Non-covered Recipient Entity
Center For Dermatology Clinical Research Inc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226116571
Principal investigator 1 Janssen Research & Development, LLC $3,040.00 05/15/2025 Non-covered Recipient Entity
Ctr For Derm Clinic Rsrch
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175170188
Principal investigator 1 SANOFI US SERVICES INC. $2,898.90 05/12/2025 Non-covered Recipient Entity
Center For Dermatology Clinical Research Inc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226116534
Principal investigator 1 Incyte Corporation $4,542.30 05/08/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240514786
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $262.90 05/08/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184194091
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,861.85 05/02/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223278902
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,000.00 05/01/2025 Non-covered Recipient Entity
Center for Dermatology Clinical Research, Inc.
A Phase 1b, Open-Label Trial to Assess Safety and Exploratory Efficacy of TEV-53408 in Participants With Vitiligo No dispute reported 06/30/2026 1244051691
Principal investigator 1 Incyte Corporation $899.10 04/28/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240514766
Principal investigator 1 Janssen Research & Development, LLC $6,160.00 04/28/2025 Non-covered Recipient Entity
Ctr For Derm Clinic Rsrch
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175170366
Principal investigator 1 Eli Lilly and Company $74,418.11 04/23/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE RANGING STUDY OF LY4100511 (DC-853) FOR THE TREATMENT OF ADULT PARTICIPANTS WITH MODERATE-TO SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 1187880897
Principal investigator 1 Incyte Corporation $4,254.30 04/15/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240514771
Principal investigator 1 SANOFI US SERVICES INC. $3,345.00 04/14/2025 Non-covered Recipient Entity
Center For Dermatology Clinical Research Inc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226116513
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,841.60 04/11/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223278008
Principal investigator 1 SANOFI US SERVICES INC. $818.75 04/10/2025 Non-covered Recipient Entity
Center For Dermatology Clinical Research Inc
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226097922
Principal investigator 1 Incyte Corporation $855.90 04/08/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240514775
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $87.00 04/07/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184181818
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $87.00 04/07/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184181820
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $87.00 04/07/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184181822
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $87.00 04/07/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184181824
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $87.00 04/07/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184181826
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $87.00 04/07/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184181828
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $87.00 04/07/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184181830
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $87.00 04/07/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184181832
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $87.00 04/07/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184181834
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $87.00 04/07/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184181836
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 04/07/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184181838
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $907.50 04/07/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184181840
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $742.50 04/07/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184181842
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $907.50 04/07/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184181844
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $907.50 04/07/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184181846
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $907.50 04/07/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184181848
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 04/07/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184181850
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 04/07/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184181852
Principal investigator 1 SANOFI US SERVICES INC. $1,534.50 04/07/2025 Non-covered Recipient Entity
Center For Dermatology Clinical Research Inc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226116490
Principal investigator 1 Incyte Corporation $3,610.80 04/01/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240514779
Principal investigator 1 Incyte Corporation $934.20 04/01/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240514783
Principal investigator 1 Eli Lilly and Company $14,549.00 03/27/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC
A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187876999
Principal investigator 1 Janssen Research & Development, LLC $4,192.00 03/27/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RES EARCH INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175345003
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,231.85 03/26/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223277039
Principal investigator 1 SANOFI US SERVICES INC. $19,298.00 03/24/2025 Non-covered Recipient Entity
Center For Dermatology Clinical Research Inc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226116478
Principal investigator 1 SANOFI US SERVICES INC. $12,300.00 03/24/2025 Non-covered Recipient Entity
Center For Dermatology Clinical Research Inc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226116482
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $12,250.00 03/20/2025 Non-covered Recipient Entity
Center for Dermatology Clinical Research, Inc.
Study Comparing Tapinarof Cream 1% To VTAMA (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis No dispute reported 06/30/2026 1244051679
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,000.00 03/20/2025 Non-covered Recipient Entity
Center for Dermatology Clinical Research, Inc.
A Phase 1b, Open-Label Trial to Assess Safety and Exploratory Efficacy of TEV-53408 in Participants With Vitiligo No dispute reported 06/30/2026 1244051687
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,000.00 03/20/2025 Non-covered Recipient Entity
Center for Dermatology Clinical Research, Inc.
A Phase 1b, Open-Label Trial to Assess Safety and Exploratory Efficacy of TEV-53408 in Participants With Vitiligo No dispute reported 06/30/2026 1244051689
Principal investigator 1 Incyte Corporation $3,716.10 03/11/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240514762
Principal investigator 1 SANOFI US SERVICES INC. $2,173.50 03/10/2025 Non-covered Recipient Entity
Center For Dermatology Clinical Research Inc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226116442
Principal investigator 1 SANOFI US SERVICES INC. $10,800.00 03/04/2025 Non-covered Recipient Entity
Center For Dermatology Clinical Research Inc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults No dispute reported 06/30/2026 1226116448
Principal investigator 1 Janssen Research & Development, LLC $3,120.00 03/03/2025 Non-covered Recipient Entity
Ctr For Derm Clinic Rsrch
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175170254
Principal investigator 1 SANOFI US SERVICES INC. $12,824.20 02/27/2025 Non-covered Recipient Entity
Center For Dermatology Clinical Research Inc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226116473
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,528.40 02/26/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223275613
Principal investigator 1 Incyte Corporation $13,230.90 02/25/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240514889
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,076.90 02/21/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223275447
Principal investigator 1 SANOFI US SERVICES INC. $12,300.00 02/18/2025 Non-covered Recipient Entity
Center For Dermatology Clinical Research Inc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226116464
Principal investigator 1 Incyte Corporation $52.48 02/05/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY COSMETIC AND LASER SURGERY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240514896
Principal investigator 1 Incyte Corporation $4.25 02/05/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY COSMETIC AND LASER SURGERY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240514900
Principal investigator 1 Incyte Corporation $93.30 02/05/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY COSMETIC AND LASER SURGERY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240514909
Principal investigator 1 Incyte Corporation $77.75 02/05/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY COSMETIC AND LASER SURGERY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240514913
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,730.80 02/03/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223274631
Principal investigator 1 Novartis Pharmaceuticals Corporation $87,328.67 02/01/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH INCORPORATION
A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup No dispute reported 06/30/2026 1190305189
Principal investigator 1 Eli Lilly and Company $11,991.00 01/29/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC
AN OPEN-LABEL, 24-WEEK STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS AND SKIN OF COLOR No dispute reported 06/30/2026 1187878901
Principal investigator 1 SANOFI US SERVICES INC. $3,964.50 01/27/2025 Non-covered Recipient Entity
Center For Dermatology Clinical Research Inc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226116457
Principal investigator 1 Janssen Research & Development, LLC $2,543.00 01/24/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RES EARCH INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175345010
Principal investigator 1 SANOFI US SERVICES INC. $1,800.00 01/21/2025 Non-covered Recipient Entity
Center For Dermatology Clinical Research Inc
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Proof-of-concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226116469
Principal investigator 1 Incyte Corporation $273.60 01/17/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240514885
Principal investigator 1 Incyte Corporation $230.00 01/16/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC
An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo No dispute reported 06/30/2026 1240514892
Principal investigator 1 Janssen Research & Development, LLC $382.00 01/16/2025 Non-covered Recipient Entity
Ctr For Derm Clinic Rsrch
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175170383
Principal investigator 1 SANOFI US SERVICES INC. $2,345.00 01/16/2025 Non-covered Recipient Entity
Center For Dermatology Clinical Research Inc
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226116520
Principal investigator 1 SANOFI US SERVICES INC. $65.00 01/16/2025 Non-covered Recipient Entity
Center For Dermatology Clinical Research Inc
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226116528
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,005.15 01/08/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223273777
Principal investigator 1 Incyte Corporation $9,396.90 01/07/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240514882
Principal investigator 1 Amgen Inc. $3,275.05 01/02/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC.
P2 Moderate-Severe pDLE No dispute reported 06/30/2026 1246640163
Principal investigator 1 Incyte Corporation $45.80 01/02/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY COSMETIC AND LASER SURGERY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240514905
Principal investigator 1 Incyte Corporation $97.08 01/02/2025 Non-covered Recipient Entity
CENTER FOR DERMATOLOGY COSMETIC AND LASER SURGERY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240514918